 CAMBRIDGE, Mass.--BUSINESS WIRE--VBI Vaccines Inc. Nasdaq: VBIV VBI, a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced positive results from multiple preclinical studies against several COVID-19 variants of concern as well as the initiation of dosing in the Phase 1b portion of the ongoing clinical study of VBIs SARS-CoV-2 vaccine candidates in approximately 80 adults age 18-54. VBIs coronavirus pipeline, whic 